摘要
目的:观察血液透析联合人促红细胞生成素治疗慢性肾衰竭(CRF)合并贫血患者的效果。方法:选取2019年6月至2021年6月该院收治的70例CRF合并贫血患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各35例。对照组采用血液透析联合多糖铁治疗,观察组采用血液透析联合人促红细胞生成素治疗,比较两组治疗前后血常规指标血红蛋白(Hb)、血细胞比容(HCT)水平,氧化应激指标[谷胱甘肽过氧化物酶(GSH-Px)、总抗氧化能力(T-AOC)、丙二醛(MDA)、超氧化物歧化酶(SOD)]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平及不良反应发生率。结果:治疗后,观察组Hb、HCT水平均高于对照组,差异有统计学意义(P<0.05);观察组GSH-PX、T-AOC及SOD水平均高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为14.29%,低于对照组的37.14%,差异有统计学意义(P<0.05)。结论:血液透析联合人促红细胞生成素治疗CRF合并贫血患者,可改善血常规指标水平,降低氧化应激反应指标水平,提高机体免疫力,且安全性高,其效果优于血液透析联合多糖铁治疗。
Objective:To observe effects of hemodialysis combined with human erythropoietin in treatment of patients with chronic renal failure(CRF)complicated with anemia.Methods:70 patients with CRF complicated with anemia who were admitted to our hospital from June 2019 to June 2021 were selected,prospectively studied and divided into control group and observation group according to the random number table method,35 cases in each group.The control group was treated with hemodialysis combined with polysaccharide iron,while the observation group was treated with hemodialysis combined with human erythropoietin.The blood routine index level hemoglobin(Hb),hematocrit(HCT),the oxidative stress index levels[glutathione peroxidase(GSH-Px),total antioxidant capacity(T-AOC),malondialdehyde(MDA),superoxide dismutase(SOD)],the T cell subset index levels(CD3^(+),CD4^(+)and CD4^(+)/CD8^(+))levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After treatment,the levels of Hb and HCT in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of GSH-PX,T-AOC and SOD in the observation group were higher than those in the control group;the level of MDA was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the observation group was 14.29%,which was lower than 37.14%in the control group,and the difference was statistically significant(P<0.05).Conclusions:Hemodialysis combined with human erythropoietin in the treatment of the patients with CRF complicated with anemia can improve the blood routine index levels,reduce the levels of stress response indicators and improve the body immunity with high safety.Moreover,it is superior to hemodialysis combined with polysaccharide iron treatment.
作者
蓝洋
LAN Yang(1^(st)Department of Internal Medicine of Tonggu County People’s Hospital,Yichun 336200 Jiangxi,China)
出处
《中国民康医学》
2022年第13期27-29,36,共4页
Medical Journal of Chinese People’s Health
